Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jul;51(7):684–688. doi: 10.1136/thx.51.7.684

Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease.

J W de Jong 1, G H Koëter 1, T W van der Mark 1, D S Postma 1
PMCID: PMC472489  PMID: 8882073

Abstract

BACKGROUND: Cessation of regular therapy with inhaled beta 2 agonists in patients with asthma may lead to a temporary deterioration of lung function and airway responsiveness. Few such studies have been reported in patients with chronic obstructive pulmonary disease (COPD), so an investigation was carried out to determine whether rebound airway responsiveness and rebound bronchoconstriction also occurs in COPD and if there is any relationship with the dose of beta 2 agonist being used. METHODS: Lung function (forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF)), airway responsiveness (PC20 methacholine (PC20)) and symptoms were assessed in a double blind, placebo controlled crossover study during and after cessation of two weeks regular treatment with placebo, and low dose (250 micrograms) and high dose (1000 micrograms) inhaled terbutaline via a dry powder inhaler (Turbohaler) all given three times a day. Sixteen non-allergic patients with COPD of mean (SD) age 58.7 (6.5) years, FEV1 57.1 (12.8)% of predicted, and reversibility on 1000 micrograms terbutaline of 4.5 (3.5)% predicted were studied. PC20 and FEV1 were measured 10, 14, 34 and 82 hours after the last inhalation of terbutaline or placebo. Measurements performed at 10, 14, and 34 hours were expressed relative to 82 hour values in each period, transformed into an area under the curve (AUC) value and analysed by ANOVA. RESULTS: Mean morning and evening PEF increased during terbutaline treatment. PC20 and FEV1 did not change after cessation of terbutaline treatment. CONCLUSIONS: Cessation of regular treatment with both low and high dose inhaled terbutaline does not result in a rebound bronchoconstriction and rebound airway responsiveness in patients with COPD.

Full text

PDF
684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Karpel J. P. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest. 1991 Apr;99(4):871–876. doi: 10.1378/chest.99.4.871. [DOI] [PubMed] [Google Scholar]
  2. Nijkamp F. P., Engels F., Henricks P. A., Van Oosterhout A. J. Mechanisms of beta-adrenergic receptor regulation in lungs and its implications for physiological responses. Physiol Rev. 1992 Apr;72(2):323–367. doi: 10.1152/physrev.1992.72.2.323. [DOI] [PubMed] [Google Scholar]
  3. O'Connor B. J., Aikman S. L., Barnes P. J. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992 Oct 22;327(17):1204–1208. doi: 10.1056/NEJM199210223271704. [DOI] [PubMed] [Google Scholar]
  4. Ollerenshaw S. L., Woolcock A. J. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):922–927. doi: 10.1164/ajrccm/145.4_Pt_1.922. [DOI] [PubMed] [Google Scholar]
  5. Phillips G. D., Finnerty J. P., Holgate S. T. Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. J Allergy Clin Immunol. 1990 Apr;85(4):755–762. doi: 10.1016/0091-6749(90)90195-a. [DOI] [PubMed] [Google Scholar]
  6. Postma D. S., de Vries K., Koëter G. H., Sluiter H. J. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis. 1986 Aug;134(2):276–280. doi: 10.1164/arrd.1986.134.2.276. [DOI] [PubMed] [Google Scholar]
  7. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  8. Sterk P. J., Fabbri L. M., Quanjer P. H., Cockcroft D. W., O'Byrne P. M., Anderson S. D., Juniper E. F., Malo J. L. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:53–83. [PubMed] [Google Scholar]
  9. Ullah M. I., Newman G. B., Saunders K. B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981 Jul;36(7):523–529. doi: 10.1136/thx.36.7.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Vathenen A. S., Knox A. J., Higgins B. G., Britton J. R., Tattersfield A. E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. doi: 10.1016/s0140-6736(88)91352-9. [DOI] [PubMed] [Google Scholar]
  11. Wahedna I., Wong C. S., Wisniewski A. F., Pavord I. D., Tattersfield A. E. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis. 1993 Sep;148(3):707–712. doi: 10.1164/ajrccm/148.3.707. [DOI] [PubMed] [Google Scholar]
  12. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES